The Indian Express·India·Thursday, September 24, 2026 at 01:00 AM

Sai Life Sciences has a growing pipeline. Can earnings catch up?

Translate

Rahul Rao

The easiest way to understand Sai Life Sciences is to follow a drug through its development journey. (Image generated using AI)

14 min readSep 24, 2026 06:30 AM IST First published on: Sep 24, 2026 at 06:30 AM IST

Sai Life Sciences had a breakout year. Revenue grew strongly, but profits grew even faster, more than doubling in FY26. The momentum hasn’t slowed down, with Q1 FY27 continuing to show double-digit growth across revenue and profitability.

At around Rs 1,584 per share, Sai’s market capitalisation is approximately Rs 33,650 crore, and the trailing P/E is above 90x.

View the original on The Indian Express →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.